Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FRAPPE: FRαDCs Plus Pembrolizumab in Advanced Ovarian Cancer
NCT05920798Phase 2Active, not recruiting
- Sponsor
- Mayo Clinic
- Start
- Sep 2023
- Primary completion
- Oct 2030
- Modality
- Prophylactic Vaccines, Peptides, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of TPIV200 in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Mayo Clinic. Started Sep 2023; status: active, not recruiting.
02
Drugs
TPIV200
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT05920798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05920798.